
Liver Diseases Treatment
Description
Global Liver Diseases Treatment Market to Reach US$37.9 Billion by 2030
The global market for Liver Diseases Treatment estimated at US$20.9 Billion in the year 2024, is expected to reach US$37.9 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Anti-Rejection Drugs/Immunosupressants, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Chemotherapy Drugs segment is estimated at 11.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$5.4 Billion While China is Forecast to Grow at 13.8% CAGR
The Liver Diseases Treatment market in the U.S. is estimated at US$5.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.8 Billion by the year 2030 trailing a CAGR of 13.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.
Global Liver Diseases Treatment Market - Key Trends & Drivers Summarized
Why Is Liver Disease Treatment Becoming a Global Priority?
The treatment of liver diseases has become a pressing healthcare priority due to the rise in conditions like hepatitis, fatty liver disease, and liver cirrhosis. Factors such as alcohol consumption, obesity, and viral infections are contributing to a growing prevalence of liver diseases worldwide. As liver conditions can lead to severe complications, including liver cancer and liver failure, early intervention and effective treatment options are essential. This increased need for liver disease treatments has spurred demand for a variety of therapeutic approaches, including antiviral drugs, lifestyle management solutions, and surgical interventions.
What Innovations Are Shaping the Future of Liver Disease Treatment?
Recent innovations in liver disease treatment are changing patient outcomes significantly. Advances in antiviral treatments have improved management options for hepatitis B and C, while immunotherapy and gene-editing techniques offer promising avenues for tackling chronic liver diseases. For conditions like fatty liver disease and liver cirrhosis, research into anti-inflammatory drugs, metabolic therapies, and regenerative medicine is providing new therapeutic possibilities. These advancements not only address symptoms but also target the root causes of liver diseases, enhancing patient recovery and potentially reversing liver damage in earlier stages.
Which Populations Are Most Affected by Liver Diseases?
Populations with high rates of alcohol consumption, obesity, and metabolic syndrome are particularly vulnerable to liver diseases. Hepatitis B and C infections are prevalent in certain regions, notably Asia and sub-Saharan Africa, making antiviral therapies essential in these areas. Additionally, the aging population faces an increased risk of liver complications, driving demand for effective treatments in older demographics. The rising prevalence of non-alcoholic fatty liver disease (NAFLD) associated with obesity has also led to heightened demand for treatment options, particularly in developed nations where dietary factors contribute to metabolic disorders.
The Growth in the Liver Diseases Treatment Market Is Driven by Several Factors
The growth in the liver diseases treatment market is driven by several factors, including the rising prevalence of lifestyle-related liver conditions, advancements in therapeutic options, and expanding healthcare access. Sedentary lifestyles, poor dietary habits, and rising obesity rates have significantly contributed to liver disease prevalence, increasing the need for effective treatments. Technological advancements in antiviral drugs, regenerative medicine, and gene therapies have broadened the range of liver disease management options. Additionally, expanding healthcare infrastructure in emerging economies has made liver disease treatments more accessible to affected populations, underscoring the market’s positive growth outlook.
SCOPE OF STUDY:The report analyzes the Liver Diseases Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Treatment Type (Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins, Corticosteroids)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 41 Featured) -
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Johnson & Johnson Pvt., Ltd.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
- Sanofi SA
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Tariff Impact on Global Supply Chain Patterns
- Liver Diseases Treatment – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Incidence of Chronic Liver Diseases and Cirrhosis
- Increased Demand for Antiviral Drugs in Hepatitis Management
- Expansion of Biologics and Gene Therapy for Liver Conditions
- Growing Demand for Liver Transplantation and Supportive Care
- Enhanced Focus on Early Detection and Preventive Treatments
- Technological Innovations in Non-invasive Liver Disease Diagnosis
- Increased Use of Targeted Therapies in Liver Cancer Treatment
- Expansion of Regenerative Medicine and Stem Cell Therapy
- Surge in Availability of Liver Disease Treatments in Emerging Markets
- Rising Demand for OTC Liver Health Supplements and Detoxifiers
- Growth in Research and Development for Fatty Liver Disease Treatments
- Increased Patient Awareness and Education on Liver Health
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Liver Diseases Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Liver Diseases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Anti-Rejection Drugs/Immunosupressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Anti-Rejection Drugs/Immunosupressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Anti-Rejection Drugs/Immunosupressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Chemotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Chemotherapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Targeted therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Targeted therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Targeted therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Anti-Viral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Iimmunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Iimmunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Iimmunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: USA Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: USA 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- CANADA
- TABLE 29: Canada Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: Canada 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- JAPAN
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 32: Japan Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: Japan 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- CHINA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 35: China Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: China Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: China 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- EUROPE
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 38: Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 39: Europe Historic Review for Liver Diseases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Europe 15-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 41: Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Europe Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Europe 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- FRANCE
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 44: France Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: France Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: France 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- GERMANY
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 47: Germany Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Germany Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Germany 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- ITALY
- TABLE 50: Italy Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Italy Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Italy 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 53: UK Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: UK Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: UK 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 56: Spain Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Spain Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Spain 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 59: Russia Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Russia Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Russia 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Rest of Europe Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Rest of Europe 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 66: Asia-Pacific Historic Review for Liver Diseases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Asia-Pacific 15-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Asia-Pacific Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Asia-Pacific 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- AUSTRALIA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 71: Australia Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Australia Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Australia 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- INDIA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 74: India Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: India Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: India 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 77: South Korea Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: South Korea Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: South Korea 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Rest of Asia-Pacific Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Rest of Asia-Pacific 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 83: Latin America Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 84: Latin America Historic Review for Liver Diseases Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Latin America 15-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 86: Latin America Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Latin America Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Latin America 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 89: Argentina Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Argentina Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Argentina 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 92: Brazil Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Brazil Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Brazil 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 95: Mexico Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Mexico Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Mexico 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of Latin America Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Rest of Latin America 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 101: Middle East Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 102: Middle East Historic Review for Liver Diseases Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Middle East 15-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 104: Middle East Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Middle East Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Middle East 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- IRAN
- TABLE 107: Iran Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Iran Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Iran 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 110: Israel Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Israel Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Israel 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Saudi Arabia Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Saudi Arabia 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 116: UAE Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: UAE Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: UAE 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: Rest of Middle East Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: Rest of Middle East 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- AFRICA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 122: Africa Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Africa Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: Africa 15-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates